NFKB1 and familial pancreatic carcinoma: We have recently demonstrated that silencing the expression or targeting the activity of TAK1 dramatically suppresses the DNA-binding activity of NF-κB leading to a proapoptotic phenotype in pancreatic cancer cells and in turn to their statistically significantly higher sensitivity to the anti-tumor activity of chemotherapeutic drugs.